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Abstract
Background: Novel psychoactive substances (NPS) are new narcotic or psychotropic drugs that are not controlled
by the United Nations drug convention that may pose a serious public health threat due to their wide availability
for purchase on the internet and in so called “head shops.” Yet, the extent of their global use remains largely
unknown. The aim of this study is to conduct a systematic review of the prevalence of NPS use in non-clinical
populations.
Methods: This is a systematic review of observational studies. Embase, MEDLINE, PubMed, Cumulative Index to
Nursing and Allied Health (CINAHL), Cochrane Library, Lilacs, Scopus, Global Health, PsychINFO, Web of Science, and
the World Health Organization (WHO) regional databases will be searched for eligible prevalence studies published
between 2010 and 2016. Data from cross-sectional studies that report the prevalence of NPS use (one or more
types) in participants (of any age) from censuses or probabilistic or convenience samples will be included. Data will
be extracted from eligible publications, using a data extraction tool developed for this study. Visual and statistical
approaches will be adopted instead of traditional meta-analytic approaches.
Discussion: This review will describe the distributions of various types of prevalence estimates of NPS use and
explore the impact of different population groups and study-related and tempo-geographical variables on
characteristics of these distributions over the period of 2010 to 2016.
Systematic review registration: PROSPERO CRD42016037020
Keywords: Novel psychoactive substances, New psychoactive substances, Legal highs, Research chemicals,
Designer drugs, Internet drugs, Club drugs, Epidemiology, Prevalence, Psychiatric morbidity
Background
Definitions, types, and effects
The authors of the United Nations Office on Drugs and
Crime report define novel psychoactive substances
(NPS) as “substances of abuse, either in a pure form or a
preparation, that are not controlled by the 1961 Single
Convention on Narcotic Drugs or the 1971 Convention
on Psychotropic Substances, but which may pose a pub-
lic health threat” [1]. “Spice,” “bath salts,” “Special K,”
and “herbal incense” are a few street names for a whole
new milieu of “designer” drugs that have seen a dramatic
increase in use across the globe. Part of the problem in
controlling the proliferation of these substances lies in
their variety, their ease of synthesis, low cost, being un-
detectable by standard toxicology screens, and resource-
ful marketing. In addition to being available from drug
traffickers, they are often sold on the internet as well as
in neighborhood head shops [2].
Although the NPS terminology seems to imply the
creation of novel drugs, many are not new. In fact, most
psychoactive drugs (that later became abused) have been
in use for at least a century. Many NPS were discovered
at the same time as other drugs, and it was simply, for
whatever reasons, these other drugs became popular.
The majority of these substances are chemicals produced
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by tweaking or altering the molecular structure of previ-
ous well-known psychoactive agents such as cannabis,
cocaine, methylenedioxymethamphetamine (or MDMA,
commonly known as ecstasy), and lysergic acid diethyl-
amide (or LSD), which are being sold as “legal highs,”
“research chemicals,” “herbal highs,” “party pills,” or
“plant food” in an attempt to stay ahead of the law pro-
hibiting the sale and use of psychoactive drugs.
NPS are formulated in a variety of forms, and when
sold in the market, many contain mixtures of different
substances some including controlled drugs. Smoked,
ingested, snorted, or injected NPS can produce a variety of
psychotropic effects, which can be similar to those related
to the controlled substances they contain or to the chemical
entities that they are derived from. Based on their clinical
effects, NPS can be classified as stimulants, empathogens-
entactogens, sedative-hypnotic-anxiolytics, dissociatives,
and hallucinogens. Alternatively, they can be classified ac-
cording to their chemical class as phenethylamines, pipera-
zines, tryptamines, synthetic cathinones, alkylindoles
(synthetic cannabinoids), and arylcyclohexylamines [3].
Pharmacologically, these substances affect dopamine,
noradrenaline, and serotonin producing a broad
spectrum of effects [1, 4]. Additionally, their potential
for addiction and toxic effects is diverse and varies de-
pending on the type of NPS. Research on the health im-
plications of most NPS is limited, but what evidence
there is suggests that the adverse effects can be just as
serious as for controlled drugs. In fact, a broad range of
negative health outcomes have been associated with
their use [1, 3, 5]. These can be physical or psycho-
logical, including cardiovascular problems, seizures,
renal failure, myocardial infarction, anxiety, agitation,
memory loss, depression, and psychosis [6–11]. Health
impacts also depend upon whether other drugs and/or
alcohol are used at the same time as NPS and the
method of use (if they are swallowed, snorted, or
injected). Deaths have been associated with drugs in
each of the main NPS groups [12].
Emergence of NPS
Since 2010, there has been a marked increase in the new
types of NPS that have been detected for the first time
with over 70% of these substances detected in the last
5 years alone [13]. From 166 new substances reported in
2009 to 348 in 2012 [14] and 450 in 2014 [15], in 2015,
the European Monitoring Centre for Drugs and Drug
Addiction detected over 100 new psychoactive substances
bringing the total number of monitored NPS to more than
560 [16]. In fact, their widespread availability through the
internet made the issue of NPS a global phenomenon with
evidence that the majority of countries that reported the
emergence of NPS were from Europe, followed by Asia,
Africa, the Americas, and Oceania [12].
Estimating prevalence of self-reported use through surveys
Despite great concern about the increasing availability
worldwide and their potential adverse effects, there has
been little consideration of the public health burden as-
sociated with NPS use. Prevalence is an epidemiological
parameter critical for generation of burden metrics, such
as the disability-adjusted life year (DALY), now largely
used by governments for prioritization of health care
and service planning [17].
To collect information about the prevalence of NPS
use in the general population, several countries have re-
cently opted for the inclusion of NPS in routine national
drug surveys. Based on data from limited number of
countries (Canada, USA, Australia, New Zealand, and
Ireland), the estimated 12 months prevalence of NPS use
for 2011–2012 period ranged from 0.4 to 5.9% [18–23].
In the US, more recent national use estimates are avail-
able from two main sources: Monitoring the Future
(MTF) study and the National Survey on Drug Use and
Health (NSDUH). MTF reported 12 months prevalence
of synthetic cannabinoids and bath salts of 10 and 1%,
respectively [24]. Meanwhile, data from five cohorts in
the NSDUH sampled from households between 2009
and 2013 reported a lifetime prevalence of 1.2% of any
NPS use. Psychedelic tryptamines (86.1%), psychedelic
phenethylamines (3.9%), and synthetic cannabinoids
(3.6%) were the top three most widely used NPS types
over this time frame [25].
Although most of the epidemiological data on NPS
use come from general population surveys, it is known
that some groups of users, particularly some marginal-
ized groups, may be underrepresented in these surveys.
This constitutes a major limitation of these surveys given
that NPS use is concentrated in certain subgroups such
as the young [26], the mentally ill [27], and other special
groups (clubbers, psychonauts (people who use sub-
stances for exploratory purposes), and people who are
lesbian, gay, bisexual, and transgender (LGBT)).
Alternative approaches to NPS prevalence estimation
in non-clinical samples (country-specific and inter-
national) utilize “flash surveys” often online-, but also
phone-based surveys, which obtain results relatively
quickly through purposive sampling with focus on spe-
cific target groups. Although largely limited by self-
selection, surveys like the Flash Eurobarometers and
Global Drugs Survey (GDS) have sample sizes of users
that are considerably bigger than most national house-
hold surveys. Therefore, provided estimates from sub-
groups of users that may be largely underrepresented in
more “traditional surveys”—those based on census or
probability samples. For example, the GDS captures NPS
use among thousands of clubbers, psychonauts, and stu-
dents, thus providing valuable information related to use
in at-high risk subpopulation groups. According to the
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most recent GDS, an 11.6% rise in last year purchase oc-
curred in the USA, the highest rate of any country
assessed. The next highest estimates were found in the
US, Canada, and the Netherlands with the lowest esti-
mate in Switzerland. Globally, the mean percentage of
NPS use was 4.8% [28].
Beyond sample designs and characteristics of partici-
pants, there are many challenges related to the evolving
nature of NPS including the lack of universal definition
of what constitutes an NPS, the large and increasing
number of substances regarded as NPS, and the differ-
ences in legislation between countries. These issues are
too complex to be adequately controlled by any one sur-
vey or a handful of large-sized surveys, if at all.
Review aims
The aim of this review is to identify and collate studies
describing the prevalence of NPS use over the period of
2010 to 2016. To achieve this aim, we will undertake a
systematic review of studies reporting point, period, and
lifetime prevalence estimates of NPS use in non-clinical
populations. We will evaluate the quality of studies and
the reported data, which will be extracted and filtered
sequentially using multiple criteria and decision rules
defined a priori. Data will be synthesized and described
using cumulative prevalence distribution plots and re-
lated summary measures. The role of temporal, geo-
graphical, and other study level variables as potential
sources of heterogeneity will also be explored graphically
and through planned statistical comparisons.
Search strategy
There is currently no universal definition for novel psy-
choactive substances (NPS). Furthermore, the extent of
variability in reported prevalence estimates of use is
largely attributed to lack of such consensus. To balance
this need for inclusiveness with practical constraints re-
lated to resources, we will use the definition proposed
by the United Nations Office on Drugs and Crime [1] to
define novel psychoactive substances (NPS). As our
interest lies mostly in self-identified NPS use, prevalence
as an epidemiological parameter, and population-based
surveys as methodological framework for capturing this
outcome of interest, we will use layman search terms
suggested in a recent review [3].
Search terms will include the following:
(“new psychoactive substances” OR “novel psycho-
active substances” OR “legal highs” OR “designer drugs”
OR “research chemicals” OR “smart drugs” OR “emer-
ging drugs of abuse” OR “club drugs” OR “herbal highs”
OR “bath salts” OR “internet drugs” OR “spice” OR “syn-
thetic drugs”) AND (“prevalence” OR “epidemiology
“OR “rate”)
The search string was developed using the Embase
(Ovid) database and lists a number of relevant medical
subject headings (MESH) and free text words for each
construct. The search terms within each concept will be
combined using the Boolean operator “or” and the terms
across the two key concepts will be combined with
“and.” We will then adapt the search strings for other
electronic databases as necessary.
In order to identify the relevant papers, we will search
the following databases:
 EMBASE/OVID (2010–2016)
 MEDLINE/OVID (2010–2016)
 Cumulative Index to Nursing and Allied Health
(CINAHL with Full Text) (2010–2016)
 The Cochrane Library (2010–2016)
 LILACS
 Scopus
 PubMed
 Global Health
 PsychINFO
 Web of Science
 World Health Organization (WHO) regional
databases including Index Medicus for the Eastern
Mediterranean Region (IMEMR), African Index
Medicus (AIM), Index Medicus for South-East Asia
Region (IMSEAR), and Western Pacific Region
Index Medicus (WPRIM)
We will search all relevant journals and manually review
the reference lists of included articles to identify additional
studies. Proceedings from scientific meetings and confer-
ence abstracts will also be included. A “Google” search will
be performed to identify relevant reports published by
international non-government organizations (e.g., WHO,
United Nations) and drug monitoring agencies as well as
local government reports. In addition, we will initiate
contact via email with scientific authorities in the field of
substance abuse from North America, South America,
Europe, Africa, Asia, Oceania, and the Middle East to
ascertain their awareness of relevant unpublished reports
or studies in progress. Only articles or scholarly works or
reports available in English, German, French, Spanish,
Arabic, and Portuguese will be included.
Inclusion and exclusion criteria
We will include cross-sectional probability or census-
based surveys that report on prevalence of any type of
NPS use in community dwelling individuals. We will ex-
clude studies based on inpatient clinical populations.
Studies that do not report prevalence of NPS use or in-
formation that would allow estimation of any type of
prevalence parameters will be excluded. If relevant data
necessary for calculating the precision of the prevalence
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estimates are missing from the original publications, we
will request this data directly from authors. Data from
international drug monitoring agencies or online surveys
will be included if available.
Condition or domain being studied
Any type of NPS use will be considered with or without
other substance use disorders. Self-identification will be
the primary method of case ascertainment in the popu-
lation of interest. Studies using recognized diagnostic
criteria, standardized instruments, or biological tests for
ascertainment of NPS use will also be included.
Participants/population
The review is concerned with respondents of any age
from non-referred samples: the general population or
community or educational institutions (schools, colleges,
and universities) with a self-reported history of recent
NPS use including initiation and recurrent use.
Intervention(s), exposure(s)
None.
Comparator(s)/control
None.
Context
Prevalence estimates will be computed based on a re-
view of studies from North America, South America,
Europe, Africa, Asia, Oceania, and the Middle East con-
ducted from 2010 to 2016. Countries will be categorized
as low, middle, and high income based on the World
Atlas Method [29].
Outcome(s)
The prevalence of NPS use is defined as the proportion
of users of any type of NPS at a given point in time
(point prevalence) or over a specified period of time
(period prevalence) or the proportion of ever users (life-
time prevalence). Synthesis of data related to the preva-
lence of any type of NPS is the primary outcome for this
review. Synthesis of data related to prevalence of com-
monly (across maximum number of studies) defined
classes of NPS would be carried out on ad hoc basis.
Synthesis of data related to the prevalence of specific
NPS is out of the scope of the current review.
Data extraction, sorting, and selection
Abstracts identified in the searches will be exported to
reference management software. Duplicate records will
be excluded (using endnote and manually). Titles and
abstracts of all identified articles will be screened for eli-
gibility based on the following criteria: (1) significant re-
views of the literature reporting NPS use prevalence; (2)
major reports on NPS; and (3) original investigations on
prevalence of substance use in non-clinical samples of
participants of any age. Two members of the research
team will conduct the screening process independently.
Disagreements will be resolved by discussion with the
remaining members of the research team and/or an in-
dependent researcher as necessary. An eligibility form
will be developed based on the inclusion/exclusion cri-
teria for this review, and reasons and information about
included/excluded studies will be recorded. A similar
process will be followed for the full-text screening stage
of the review.
We will develop a data extraction tool, which will be
piloted on a random sample of papers to check for ac-
curacy and consistency. The following information about
each study will be extracted:
1. Study or report characteristics: author (s), study
year, country, publication type, language(s)
2. Study design/methodology: study design, sample
size, sampling strategy, recruitment methods, sample
coverage (community, country, region), survey
administration modality
3. Parameter of interest: prevalence type including
point-, period-, lifetime-prevalence, and non-
specified. Type of parameter information available
(numerator and denominator or prevalence and de-
nominator or prevalence and standard error, or
prevalence and 95% confidence intervals)
4. NPS-related information: definition(s), wording of
use questions, level of information discrete drugs,
drug classes, or no information, sources of reported
NPS use (proxy or non-proxy), point of purchase
5. Special groups: information on type of population
groups (students, psychiatric morbidity clubbers/
ravers, psychonaut, and LGBT
6. Country-level variables: country’s economic status/
measure of wealth, geographical region
7. Person-level variables: age and gender
Included studies will be categorized and sequentially
filtered by a series of criteria including population group
(households, schools, and other special groups), survey
mode (face-to-face, phone, internet), sample type (prob-
ability, census, convenience), prevalence type (point,
period, lifetime, and non-specified), and NPS type (any
NPS versus specific NPS types—chemical drug name,
chemical class name, “street” name). Rules will be devel-
oped, pretested, and systematically applied to allow care-
ful selection of prevalence data without counting the
same individuals more than once within the same study
or in different studies. Specifically, selection rules that
prioritize the inclusion of the single most informative
and/or representative prevalence estimate will be
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developed and applied to situations where overall (com-
bined) and class-specific prevalence estimates of NPS
are reported by the same study. These rules will be de-
veloped ad hoc (if we find that most studies were report-
ing the prevalence of specific classes—e.g., synthetic
cannabinoids, synthetic cathinones—as opposed to any
NPS use then when we come across a study that reports
both, we will choose the former type of estimates).
Prevalence estimates will be extracted separately for
those with and without psychiatric morbidity. To avoid
duplication, where person- and psychiatric-specific esti-
mates are reported by the same study, only the latter will
be included in the analyses.
Age-specific or overall age prevalence estimates
(range) will be extracted separately. To ensure independ-
ence of observations, where both are reported, only the
latter will be included. Where only age-specific estimates
are reported, these will be combined to calculate the
overall age prevalence by summing the number of cases
across each age group and dividing by the summed de-
nominator across each age group.
Risk of bias (quality) assessment
A tool specifically designed for the assessment of the
risk of bias and methodological quality of population-
based prevalence studies will be used for the purpose of
this review [30]. Studies will be graded using this tool,
which will be adapted to incorporate established criteria
for high-quality surveys as per evaluation framework put
forth by the American Association of Public Opinion
Research [31]. Studies will also be graded for the quality
of reporting including information about how NPS was
defined and operationalized.
Strategy for data synthesis
Setting aside variability due to methodological issues re-
lated to quality of studies, reporting, and measurement,
we anticipate that the underlying frequency distributions
of NPS used to be largely heterogeneous. Prevalence es-
timates of NPS use are expected to vary widely between
countries/regions and time periods due to differences in
population characteristics and socio-economic and ex-
posure levels. Therefore, traditional meta-analytic ap-
proaches of pooling data to produce a single estimate of
prevalence may be conceptually problematic, potentially
contributing to loss of informative variation about the
prevalence of NPS use. For this reason, we will use de-
scriptive approaches to reporting variations in the distri-
butions of different types of prevalence data across
studies. Cumulative prevalence distributions will be plot-
ted for each prevalence type (point, period, and lifetime)
and summary statistics for each plot will be provided in
accompanying tables with quantiles (including median,
mean, interquartile range, and standard deviations).
Potential sources of heterogeneity can be investigated
through sorting the data according to various rules and
comparing the resulting distributions i.e., assessment of
significant distributional changes in the cumulative
prevalence plots resulting from the inclusion/exclusion
of different subsets of studies [32].
In this respect, we plan to conduct a series of sensitiv-
ity analyses related to understanding variation in NPS
use prevalence by country-level variables (economic sta-
tus, region), population groups (students, people with
psychiatric comorbidity, ravers/clubbers, and people
who are gay or lesbian), and study-level variables (survey
mode, sample type). Additionally, we aim to understand
the role of changing definitions of NPS by detecting sig-
nificant differences in the distribution of prevalence esti-
mates when data are sorted by studies applying different
definitions of NPS. Comparisons between the distribu-
tions of proportion estimates for different groups (e.g.,
males versus females) or for different levels of other var-
iables of interest will be described using the ratio of the
measures of central tendency for each variable level (e.g.,
male to female prevalence estimate ratio). Necessary
multiple-comparison adjustments to the tests of signifi-
cance will be carried out for any post hoc analyses.
Temporal trends will also be investigated by visually
inspecting and testing for significant distributional
changes in the cumulative prevalence plots and corre-
sponding changes in the effect size of the prevalence esti-
mates in response to the stepwise addition of studies after
sorting data in chronological order [33]. This allows esti-
mation of the contribution of studies over time.
Discussion
This systematic review will produce and describe preva-
lence distributions of NPS use based on data collected
by studies conducted between 2010 to 2016 in North
America, South America, Europe, Africa, Asia, Oceania,
and the Middle East. This review will also explore study-,
person-, group-, and NPS-related variables contributing to
the heterogeneity of these distribtutions providing a much-
needed picture of the extent of variation in prevalence of
NPS use across different populations and regions of the
world since 2010. Researchers, policy makers, and public
health stakeholders will use evidence resulting from the
study to set research, policy, and program priorities for sur-
veillance purposes, prevention, and provision of adequate
clinical services. This information will also provide neces-
sary insight into the effects of international efforts at policy
and control of NPS by identifying “hot spots” and potential
“at risk populations,” detailing the relative role of environ-
mental factors in the formation of problematic NPS use.
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